Researchers from groups led by Dr. Emilio Parisini (LIOS, Biotechnology group) and Dr. Olga Bruno have designed, synthesized, and performed the biological evaluation and structural
Enantiopure secondary alcohols are valuable intermediates in medicinal chemistry since many marketed drugs such as crizotinib, lorlatinib, cenobamate, atomoxetine, and duloxetine are derivatives of chiral
Propylamycin is a next-generation aminoglycoside antibiotic that displays increased antibacterial potency. But due to the hydroxy group in propylamycin 5′′-position, it is inactivated by aminoglycoside
Researcher group from Latvian Institute of Organic Synthesis have investigated the molecular mechanisms of cellular insulin resistance. They discovered that long-chain acylcarnitines decrease phosphorylation of
The Covid-19 pandemic is one of the greatest challenges modern medicine has ever faced. While repurposing studies of existing drugs haven’t shown very promising results,
RISK-HUNT3R is the new European effort hosting world-leading experts from many different disciplines aiming to develop a novel and modular framework for animal-free next-generation risk
Ansis Maleckis (Latvian Institute of Organic Synthesis), Iresha D. Herath and Gottfried Otting (Australian National University) have demonstrated the use of 13C labeled indoles and
The new A4L_ACTIONS project just started The kick-off conference of the H2020 project A4L_ACTIONS, connecting thirteen members from the strategic partnership called Alliance4Life, took place
EU-OPENSCREEN integrates high-capacity screening platforms throughout Europe, which jointly use a rationally selected compound collection, comprising up to 140.000 commercial and proprietary compounds collected from
Researchers at the Organic Synthesis Methodology Group (Latvian Institute of Organic Synthesis) and the Francis Crick Institute have designed potential drug-like compounds which effectively block
A straightforward and atom‐economic method for the functionalization of short selenocystine‐containing peptides proposed by researchers from the Pharmacomodulators Synthesis Group (LIOS) has been published in
The stereoselective total synthesis of the proposed structure of a potent serotonin 5-HT1A receptor agonist uncarialin A elaborated by LIOS scientists have been published in
Joint research on the electrosynthesis of hypervalent bromine by Edgars Suna and Igors Sokolovs (IOS, Laboratory of Advanced Technologies for Organic Synthesis) and scientists from
A review article on isolation, chemistry, and biology of pyrrolo[1,4]benzodiazepine natural products by Gints Smits group (Laboratory of CNS Active Compounds) has been published in
Prof. Kristaps Jaudzems (IOS, Laboratory of Physical Organic Chemistry) has given a lecture on artificial spider silk at the largest deep tech industry event in
Researchers from the Pharmacomodulators Synthesis Group (LIOS) have demonstrated a convenient one-pot process for the construction of selanyl and tellanyl substituted N-polyaromatic systems (up to
Joint research on the structural analysis of an antigen chemically‐coupled on virus‐like particles by Kristaps Jaudzems (IOS, Laboratory of Physical Organic Chemistry) and scientists from
Continuing studies of cobalt-catalyzed C(sp2)–H carbonylation reactions Liene Grigorjeva et al. (Organic Synthesis Methodology group) have reported an efficient protocol for the synthesis of 1,2-dihydroisoquinolinone
Janis Veliks et al. (Organic Synthesis Methodology group) have reported a new strategy of synthesizing monofluorinated five-membered rings via fluoromethylene transfer. This approach has been published
Joint research by Pavel Arenyan group (IOS) and scientists from the Kaunas University of Technology on new OLEDs has been published in the Journal of
Joint research done by scientists from the Laboratory of Membrane Active Compounds and β-diketones (IOS) and the University of Latvia on physicochemical properties of amphiphilic
A researcher group from LIOS has proposed a very simple method for a fast determination of NMR yield in the organic synthesis lab by determining
Researchers led by Professor Zhang (US) have reported that BBOX1 is a potential therapeutic target in triple negative breast cancer. Effective BBOX1 inhibitors for the
Scientists from the Laboratory of Pharmaceutical Pharmacology (LIOS) in collaboration with colleges from COST Action “EU‐CARDIOPROTECTION” in their latest review article explores the mechanisms of
Input your search keywords and press Enter.